Modification of escalated beacopp with dacarbazine / procarbazine substitution reduces red cell transfusion requirements and may shorten time to menstrual period recovery

Abstract

It is increasingly common practice to modify escalated BEACOPP (eBPP) by removing oral procarbazine and replacing with intravenous dacarbazine (250mg/m2 D2‐3), hoping to reduce haematopoietic stem cell and gonadal toxicity. However, published data on the so‐called ‘escalated BEACOPDac (eBPDac)’ regimen are limited.